Investing.com - Effector Therapeutics (NASDAQ: EFTR) reported second quarter EPS of $-0.170, $0.03 better than the analyst estimate of $-0.198. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Effector Therapeutics's stock price closed at $0.740. It is up 15.810% in the last 3 months and up 16.250% in the last 12 months.
Effector Therapeutics saw 0 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Effector Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Effector Therapeutics's Financial Health score is "weak performance".
Check out Effector Therapeutics's recent earnings performance, and Effector Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar